In some studies, an influence on OS is seen with IDH1 mutations for patients with CN-AML or intermediate risk group according to the FLT3/NPM1 status[13-15,23,28], while other groups could not detect any impact on survival with mutated IDH1 gene, which is in accordance with our results[9,20,24,26]. This evidence concerns the gene FLT3 and acute myeloid leukemia.